Verbesserung der Knöchel-Plantarflexor-Funktion bei Zerebralparese
Verbesserung der Funktion des Knöchel-Plantarflexors und der Gehfähigkeit bei Kindern mit Zerebralparese
The first specific aim is to quantify improvement in ankle muscle function and functional mobility following targeted ankle resistance gait training in ambulatory children with cerebral palsy (CP). The primary hypothesis for the first aim is that targeted ankle resistance training will produce larger improvements in lower-extremity motor control, gait mechanics, and clinical measures of mobility assessed four- and twelve-weeks post intervention compared to standard physical therapy and standard gait training. The second specific aim is to determine the efficacy of adaptive ankle assistance to improve capacity and performance during sustained, high-intensity, and challenging tasks in ambulatory children with CP. The primary hypothesis for the second aim is that adaptive ankle assistance will result in significantly greater capacity and performance during the six-minute-walk-test and graded treadmill and stair stepping protocols compared to walking with ankle foot orthoses and walking with just shoes.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
A child's ability to walk effectively is essential to their physical health and general well-being. Unfortunately, many children with cerebral palsy (CP), the most common cause of pediatric physical disability, have difficulty walking and completing higher-intensity ambulatory tasks. This leads to children with CP engaging in levels of habitual physical activity that are well below guidelines and those of children without disabilities, which in turn contributes to many secondary conditions, including metabolic dysfunction and cardiovascular disease. There is broad clinical consensus that plantarflexor dysfunction is a primary contributor to slow, inefficient, and crouched walking patterns in CP; individuals with CP need more effective treatments and mobility aids for plantarflexor dysfunction. To meet this need, this proposal aims to evaluate a holistic strategy to address impaired mobility from plantarflexor dysfunction in CP using a lightweight, dual-mode (assistive or resistive) wearable robotic device. This strategy combines two complementary techniques: (1) targeted ankle resistance for neuromuscular gait training that provides precision therapy to elicit long-term improvements in ankle muscle function, and (2) adaptive ankle assistance to make walking easier during sustained, high-intensity, or challenging tasks.
Aim 1: Quantify improvement in ankle muscle function and functional mobility following targeted ankle resistance gait training in ambulatory children with CP Approach - Repeated Measures (RM) and randomized controlled trial: The investigators will compare functional outcomes following targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard physical therapy (RM) and vs. dose-matched standard treadmill training (randomized controlled trial). Primary Hypothesis: Targeted ankle resistance training will produce larger improvements in lower-extremity motor control, gait mechanics, and clinical measures of mobility assessed four- and twelve-weeks post intervention compared to the control conditions.
Aim 2: Determine the efficacy of adaptive ankle assistance to improve capacity and performance during sustained, high-intensity, and challenging tasks in ambulatory children with CP Approach - Repeated Measures: The investigators will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid) during (a) 6-minute-walk-test, (b) extended-duration over-ground walking (sustained), (c) graded treadmill (high-intensity), and (d) stair-stepping (challenging) protocols. Task capacity and performance will be measured by duration, metabolic cost, speed, and stride length, as applicable. Primary Hypothesis: Adaptive ankle assistance will result in significantly greater capacity and performance compared to the control conditions.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55101
- Gillette Children's Specialty Healthcare
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Ages between 8 and 21 years old, inclusive. Diagnosis of CP and a pathological gait pattern caused by ankle dysfunction.
- Able to understand and follow simple directions (based on parent report, if needed) and walk at least 30 feet with or without a walking aid (Gross Motor Function Classification System (GMFCS) Level I-III).
- At least 20° of passive plantar-flexion range of motion.
Exclusion Criteria:
- Concurrent treatment other than those assigned during the study.
- A condition other than CP that would affect safe participation.
- Surgical intervention within 6 months of participation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Device resisted gait training (treatment)
We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training. |
A lightweight resistive wearable ankle robotic device. |
|
Experimental: Standard gait training (control)
We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training. |
Standard gait training without a device. |
|
Experimental: Comparison to Standard PT (within subjects control)
We will use a within-subject repeated measures design to compare both gait training groups to matched standard physical therapy. |
Physical therapy without a device. |
|
Experimental: Device assisted ambulation
We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid). |
A lightweight assistive wearable ankle robotic device. |
|
Experimental: Passive brace assisted ambulation
We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid). |
Standard ankle foot orthosis |
|
Experimental: No ankle aid ambulation
We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid). |
Walking without a device |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in preferred walking speed
Zeitfenster: Immediately after the intervention
|
Participant's preferred walking speed compared after to before the intervention |
Immediately after the intervention
|
|
Change in preferred walking speed
Zeitfenster: 2 weeks after the intervention
|
Participant's preferred walking speed compared after to before the intervention |
2 weeks after the intervention
|
|
Change in preferred walking speed
Zeitfenster: 12 weeks after the intervention
|
Participant's preferred walking speed compared after to before the intervention |
12 weeks after the intervention
|
|
Change in similarity of plantarflexor muscle activity
Zeitfenster: Immediately after the intervention
|
Similarity of the plantarflexor muscle activity profile across the gait cycle, measured using surface electromyography (the measurement tool) of the soleus muscle, to the average unimpaired electromyography muscle activity profile, as calculated via cross-correlation coefficient. A higher value indicates greater similarity. |
Immediately after the intervention
|
|
Change in similarity of plantarflexor muscle activity
Zeitfenster: 2 weeks after the intervention
|
Similarity of the plantarflexor muscle activity profile across the gait cycle, measured using surface electromyography (the measurement tool) of the soleus muscle, to the average unimpaired electromyography muscle activity profile, as calculated via cross-correlation coefficient. A higher value indicates greater similarity. |
2 weeks after the intervention
|
|
Change in similarity of plantarflexor muscle activity
Zeitfenster: 12 weeks after the intervention
|
Similarity of the plantarflexor muscle activity profile across the gait cycle, measured using surface electromyography (the measurement tool) of the soleus muscle, to the average unimpaired electromyography muscle activity profile, as calculated via cross-correlation coefficient. A higher value indicates greater similarity. |
12 weeks after the intervention
|
|
Change in 6-minute-walk-test distance
Zeitfenster: Immediately after the intervention
|
Distance traveled in 6 minutes during a 6-minute-walk-test protocol. A longer distance indicates greater walking capacity. |
Immediately after the intervention
|
|
Change in 6-minute-walk-test distance
Zeitfenster: 2 weeks after the intervention
|
Distance traveled in 6 minutes during a 6-minute-walk-test protocol. A longer distance indicates greater walking capacity. |
2 weeks after the intervention
|
|
Change in 6-minute-walk-test distance
Zeitfenster: 12 weeks after the intervention
|
Distance traveled in 6 minutes during a 6-minute-walk-test protocol. A longer distance indicates greater walking capacity. |
12 weeks after the intervention
|
|
Change in variance in muscle activity
Zeitfenster: Immediately after the intervention
|
Variance in muscle activity accounted for by one muscle synergy assessed using surface electromyography (the measurement tool) of the soleus, tibialis anterior, medial hamstrings, and vastus medialis. Muscle synergies will be computed from non-negative matrix factorization. Lower variance accounted for by one muscle synergy indicates a desired greater complexity of motor control. |
Immediately after the intervention
|
|
Change in variance in muscle activity
Zeitfenster: 2 weeks after the intervention
|
Variance in muscle activity accounted for by one muscle synergy assessed using surface electromyography (the measurement tool) of the soleus, tibialis anterior, medial hamstrings, and vastus medialis. Muscle synergies will be computed from non-negative matrix factorization. Lower variance accounted for by one muscle synergy indicates a desired greater complexity of motor control. |
2 weeks after the intervention
|
|
Change in variance in muscle activity
Zeitfenster: 12 weeks after the intervention
|
Variance in muscle activity accounted for by one muscle synergy assessed using surface electromyography (the measurement tool) of the soleus, tibialis anterior, medial hamstrings, and vastus medialis. Muscle synergies will be computed from non-negative matrix factorization. Lower variance accounted for by one muscle synergy indicates a desired greater complexity of motor control. |
12 weeks after the intervention
|
|
Change in stride length
Zeitfenster: Immediately after the intervention
|
Participant stride length during walking. Longer stride length is desired. |
Immediately after the intervention
|
|
Change in stride length
Zeitfenster: 2 weeks after the intervention
|
Participant stride length during walking. Longer stride length is desired. |
2 weeks after the intervention
|
|
Change in stride length
Zeitfenster: 12 weeks after the intervention
|
Participant stride length during walking. Longer stride length is desired. |
12 weeks after the intervention
|
|
Change in stride-to-stride variability stride length
Zeitfenster: Immediately after the intervention
|
Stride-to-stride variability of lower-extremity muscle activity for the soleus, tibias anterior, vastus lateralis, and medial hamstrings, measured via surface electromyography and calculated as the variance ratio across strides. |
Immediately after the intervention
|
|
Change in stride-to-stride variability stride length
Zeitfenster: 2 weeks after the intervention
|
Stride-to-stride variability of lower-extremity muscle activity for the soleus, tibias anterior, vastus lateralis, and medial hamstrings, measured via surface electromyography and calculated as the variance ratio across strides. |
2 weeks after the intervention
|
|
Change in stride-to-stride variability stride length
Zeitfenster: 12 weeks after the intervention
|
Stride-to-stride variability of lower-extremity muscle activity for the soleus, tibias anterior, vastus lateralis, and medial hamstrings, measured via surface electromyography and calculated as the variance ratio across strides. |
12 weeks after the intervention
|
|
Change in walking posture
Zeitfenster: Immediately after the intervention
|
Peak Lower-extremity joint angles summed across the ankle, knee, and hip joints, measured using motion capture (the measurement tool). |
Immediately after the intervention
|
|
Change in walking posture
Zeitfenster: 2 weeks after the intervention
|
Peak Lower-extremity joint angles summed across the ankle, knee, and hip joints, measured using motion capture (the measurement tool). |
2 weeks after the intervention
|
|
Change in walking posture
Zeitfenster: 12 weeks after the intervention
|
Peak Lower-extremity joint angles summed across the ankle, knee, and hip joints, measured using motion capture (the measurement tool). |
12 weeks after the intervention
|
|
Change in Gross Motor Function Measure-66 sec. D&E
Zeitfenster: Immediately after the intervention
|
Gross Motor Function Measure - 66, sections (D) standing, and (E) walking, running and jumping. Higher scores are better, and range from 0-3 for each measure. |
Immediately after the intervention
|
|
Change in Gross Motor Function Measure-66 sec. D&E
Zeitfenster: 2 weeks after the intervention
|
Gross Motor Function Measure - 66, sections (D) standing, and (E) walking, running and jumping. Higher scores are better, and range from 0-3 for each measure. |
2 weeks after the intervention
|
|
Change in Gross Motor Function Measure-66 sec. D&E
Zeitfenster: 12 weeks after the intervention
|
Gross Motor Function Measure - 66, sections (D) standing, and (E) walking, running and jumping. Higher scores are better, and range from 0-3 for each measure. |
12 weeks after the intervention
|
|
Change in plantar-flexor strength
Zeitfenster: Immediately after the intervention
|
Plantar-flexor muscle strength measured via hand-held dynamometry. |
Immediately after the intervention
|
|
Change in plantar-flexor strength
Zeitfenster: 2 weeks after the intervention
|
Plantar-flexor muscle strength measured via hand-held dynamometry. |
2 weeks after the intervention
|
|
Change in plantar-flexor strength
Zeitfenster: 12 weeks after the intervention
|
Plantar-flexor muscle strength measured via hand-held dynamometry. |
12 weeks after the intervention
|
|
Distance traveled
Zeitfenster: 1 day
|
Distance traveled during the 6-minute-walk-test, and treadmill and stair stepper bruce protocols. |
1 day
|
|
Metabolic cost of transport from indirect calorimetry
Zeitfenster: 1 day
|
Metabolic cost estimated from a wearable indirect calorimetry system during the 6-minute-walk-test, and treadmill and stair stepper bruce protocols |
1 day
|
|
Subject perceived exertion
Zeitfenster: 1 day
|
Subject perceived exertion (validated pictorial pediatric exertion scale). The scale is from 1-10, where a higher number indicates more effort. |
1 day
|
|
Average muscle activity
Zeitfenster: 1 day
|
Average stance-phase plantar flexor muscle activity assessed through surface electromyography of the soleus muscle. |
1 day
|
|
Heart Rate
Zeitfenster: 1 day
|
Average heart rate during each testing condition measured via chest-mounted heart rate monitor. |
1 day
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Zach F Lerner, PhD, Northern Arizona University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 1R01HD107277 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .